Device Optics

Tecnis Iol

Payments companies reported to CMS as associated with Tecnis Iol. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$2.0Massociated payments (2023-2025)

4,090clinicians with associated payments

4companies reporting

By year

2023 $658K

2024 $752K

2025 $625K

Payments reported as associated with Tecnis Iol, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Ophthalmology $1.8M

Optometrist $100K

Cornea and External Diseases Specialist $80K

Glaucoma Specialist $13K

Retina Specialist $6,670

Internal Medicine $4,156

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Tecnis Iol

These are the largest totals companies reported as associated with Tecnis Iol. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Ravi Patel	Eatontown, NJ	Ophthalmology	$162,015.86
Carlton Yuen	Honolulu, HI	Ophthalmology	$120,957.27
Niraj Desai	Cumming, GA	Ophthalmology	$89,505.03
Alexander Knezevic	Los Angeles, CA	Ophthalmology	$76,568.64
Joaquin De Rojas	Venice, FL	Ophthalmology	$72,812.86
Zaina Al-Mohtaseb	Houston, TX	Ophthalmology	$60,096.05
Jeremy Kieval	Lexington, MA	Ophthalmology	$56,686.25
Douglas Grayson	Iselin, NJ	Ophthalmology	$48,276.58
David Hamilton	Los Angeles, CA	Ophthalmology	$46,984.60
Iqbal Ahmed	Salt Lake City, UT	Ophthalmology	$43,718.28

Prescribed Tecnis Iol?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.